Hyperkalemia

American Family Physician

Volumn 73, Issue 2, 2006, Pages 283-290

  Hollander Rodriguez, Joyce C ^a,b,c   Calvert Jr , James F ^a,c,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Cascades East Family Practice Residency Program   (United States)

^d Merle West Center for Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMINO ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CREATININE; CYCLOSPORIN A; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DROSPIRENONE PLUS ETHINYLESTRADIOL; EPLERENONE; FLUORIDE; FUROSEMIDE; GLUCOSE; HEPARIN DERIVATIVE; HERBACEOUS AGENT; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PENTAMIDINE ISETHIONATE; POLYSTYRENESULFONATE SODIUM; POTASSIUM; PYRROLE DERIVATIVE; SALBUTAMOL; SODIUM CHLORIDE; SPIRONOLACTONE; SUXAMETHONIUM; TACROLIMUS; TRIAMTERENE; TRIMETHOPRIM; UNINDEXED DRUG;

ADRENAL INSUFFICIENCY; DEHYDRATION; DIABETIC NEPHROPATHY; DIAGNOSTIC PROCEDURE; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERKALEMIA; HYPOALDOSTERONISM; KALIURESIS; LONG TERM CARE; METABOLIC DISORDER; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; POTASSIUM TRANSPORT; POTASSIUM URINE LEVEL; REVIEW; RISK REDUCTION; URINE OSMOLALITY;

ALGORITHMS; HUMANS; HYPERKALEMIA;

EID: 31544440414     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998;158:917-24.
2. Gennari FJ. Disorders of potassium homeostasis. Hypokalemia and hyperkalemia. Crit Care Clin 2002;18:273-88.
3. Kim HJ, Han SW. Therapeutic approach to hyperkalemia. Nephron 2002;92(suppl 1):33-40.
4. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000;109:307-14.
5. Perazella MA. Drug-induced hyperkalemia [Letter Reply]. Am J Med 2002;112:334-5.
6. Pantanowitz L. Drug-induced hyperkalemia [Letter]. Am J Med 2002;112:334.
7. Huggins RM, Kennedy WK, Melroy MJ, Tollerton DG. Cardiac arrest from succinylcholine-induced hyperkalemia. Am J Health Syst Pharm 2003;60:694-7.
8. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.
9. Witham MD, Gillespie ND, Struthers AD. Hyperkalemia after the publication of RALES. N Engl J Med 2004;351:2448-50.
10. Adhiyaman V, Asghar M, Oke A, White AD, Shah IU. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med 2001;94:512-4.
11. DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980;17:118-34.
12. Grande Villoria J, Macias Nunez JF, Miralles JM, De Castro del Pozo S, Tabernero Romo JM. Hyporeninemic hypoaldosteronism in diabetic patients with chronic renal failure. Am J Nephrol 1988;8:127-37.
13. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators. N Engl J Med 1999;341:709-17.
14. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [published corrections appear in N Engl J Med 2000;342:1376; N Engl J Med 2000;342:748]. N Engl J Med 2000;342:145-53.
15. McFarlane SI, Sowers JR. Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab 2003;88:516-23.
16. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001;111:64-7.
17. Smith JC, Siddique H, Corrall RJ. Misinterpretation of serum cortisol in a patient with hyponatremia. BMJ 2004;328:215-6.
18. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency [published correction appears in Ann Intern Med 2004;140:315]. Ann Intern Med 2003;139:194-204.
19. Becker KL. Principles and practice of endocrinology and metabolism. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
20. White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med 1994;331:250-8.
21. Slovis C, Jenkins R. ABC of clinical electrocardiography: conditions not primarily affecting the heart. BMJ 2002;324:1320-3.
22. Ethier JH, Kamel KS, Magner PO, Lemann J JR, Halperin ML. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am J Kidney Dis 1990;15:309-15.
23. Greenburg A, Cheung AK; National Kidney Foundation. Primer on kidney diseases. 4th ed. Philadelphia: Elsevier Saunders, 2005.
24. Watanabe T, Nitta K. Transient hyporeninemic hypoaldosteronism in acute glomerulonephritis. Pediatr Nephrol 2002;17:959-63.
25. Martinez-Vea A, Bardaji A, Garcia C, Oliver JA. Severe hyperkalemia with minimal electrocardiographic manifestations: a report of seven cases. J Electrocardiol 1999;32:45-9.
26. Szerlip HM, Weiss J, Singer I. Profound hyperkalemia without electrocardiographic manifestations. Am J Kidney Dis 1986;7:461-5.
27. Charytan D, Goldfarb DS. Indications for hospitalization of patients with hyperkalemia. Arch Intern Med 2000;160:1605-11.
28. Williams ME. Endocrine crisis. Hyperkalemia. Crit Care Clin 1991;7:155-74.
29. Davey M. Calcium for hyperkalemia in digoxin toxicity. Emerg Med J 2002;19:183.
30. Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol 1998;9:1535-43.
31. Lens XM, Montoliu J, Cases A, Campistrol JM, Revert L. Treatment of hyperkalemia in renal failure: salbutamol v. insulin. Nephrol Dial Transplant 1989;4:228-32.
32. Kim HJ. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. Nephron 1996;72:476-82.
33. Gerstman BB, Kirkman R, Platt R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am J Kidney Dis 1992;20:159-61.